Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma

Table 3 Univariate and multivariate analysis of Cezanne associated with survival and recurrence in HCC patients

Variables*	OS				TTR
	Univariate	Multivariate			Univariate	Multivariate
	P -value	P -value	HR	95% CI	P -value	P -value	HR	95% CI
Gender (Female vs. Male)	NS	NS			NS	NS
Age, years (≤50 vs. > 50)	NS	NS			NS	NS
AFP (ng/mL) (≤20 vs. > 20)	0.016	NS			0.049	NS
HBsAg (Negative vs. Positive)	NS	NS			NS	NS
GGT (U/l) (≤50 vs. > 50)	0.001	NS			0.006	NS
Liver cirrhosis (No vs. Yes)	0.006	0.008	2.216	1.232-3.985	0.012	0.017	1.865	1.115-3.117
Tumor size (cm) (≤5 vs. > 5)	<0.001	0.032	1.616	1.042-2.504	<0.001	0.004	1.866	1.222-2.849
Tumor number (Single vs. Multiple)	NS	NS			0.025	NS
Satellite nodule (No vs. Yes)	NS	NS			0.009	NS
Tumor capsule (No/incomplete vs. Complete)	NS	NS			NS	NS
Tumor differentiation (I-II vs. III-IV)	NS	NS			NS	NS
Vascular invasion (No vs. Yes)	<0.001	<0.001	2.941	1.706-5.072	<0.001	<0.001	2.471	1.475-4.138
Cezanne (Low versus High)	<0.001	<0.001	0.352	0.226-0.546	<0.001	<0.001	0.354	0.237-0.528

*TNM stage and BCLC stage was combined with several clinical indexes such as tumor size, number and tumor thrombus; we did not enter the TNM stage and BCLC stage into multiple analysis with these indexes to avoid any bias in analysis.
GGT gamma-glutamyltransferase, AFP α-fetoprotein, OS overall survival, TTR time to recurrence, NS not significant, HR hazard ratio, CI confidential interval.

ISSN: 1479-5876